Oral bisphosphonates reduce the risk of clinical fractures in glucocorticoid-induced osteoporosis in clinical practice (Q46244082)

20 December 2017

title

Oral bisphosphonates reduce the risk of clinical fractures in glucocorticoid-induced osteoporosis in clinical practice (English)

1 reference

20 December 2017

glucocorticoid-induced osteoporosis

main subject

osteoporosis

0 references

1 reference

T Thomas

1

1 reference

20 December 2017

S Horlait

2

1 reference

20 December 2017

J D Ringe

3

1 reference

20 December 2017

A Abelson

4

1 reference

20 December 2017

D T Gold

5

1 reference

20 December 2017

P Atlan

6

1 reference

20 December 2017

J L Lange

7

1 reference

20 December 2017

language of work or name

English

0 references

publication date

27 June 2012

1 reference

20 December 2017

Osteoporosis International

published in

1 reference

20 December 2017

volume

24

1 reference

20 December 2017

issue

1

1 reference

20 December 2017

page(s)

263-269

1 reference

20 December 2017

Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study

cites work

1 reference

https://api.crossref.org/works/10.1007/S00198-012-2060-4

Use of oral corticosteroids in the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-012-2060-4

Use of oral corticosteroids and risk of fractures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-012-2060-4

Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-012-2060-4

Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-012-2060-4

Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-012-2060-4

RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-012-2060-4

Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the eValuation of IBandronate Efficacy (VIBE) database fracture study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-012-2060-4

Longitudinal change in clinical fracture incidence after initiation of bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-012-2060-4

Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-012-2060-4

Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-012-2060-4

Fractures attributable to osteoporosis: report from the National Osteoporosis Foundation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-012-2060-4

Loss of treatment benefit due to low compliance with bisphosphonate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-012-2060-4

Fracture outcomes related to persistence and compliance with oral bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-012-2060-4

Relationship between duration of compliant bisphosphonate use and the risk of osteoporotic fractures .

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-012-2060-4

Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-012-2060-4

Impact of compliance and persistence with bisphosphonate therapy on health care costs and utilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-012-2060-4

Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-012-2060-4

Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-012-2060-4

Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-012-2060-4

Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-012-2060-4

Cost-effectiveness of multifaceted evidence implementation programs for the prevention of glucocorticoid-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-012-2060-4

The potential impact of new National Osteoporosis Foundation guidance on treatment patterns

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-012-2060-4

Identification of fractures from computerized medicare files

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-012-2060-4

Assessment of compliance with osteoporosis treatment and its consequences in a managed care population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00198-012-2060-4

Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study

21 January 2018

1 reference

12 December 2020

Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study

1 reference

12 December 2020

Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group

1 reference

12 December 2020

Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy

1 reference

12 December 2020

Oral glucocorticoid use is associated with an increased risk of fracture

1 reference

12 December 2020

10.1007/S00198-012-2060-4

Identifiers

DOI

1 reference

20 December 2017

1 reference

20 December 2017